Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 12/20 | 0.44 |
| ▸ | DPP8 | Q6V1X1 | 11/20 | 0.44 |
| ▸ | DPP7 | Q9UHL4 | 7/20 | 0.44 |
| ▸ | DPP9 | Q86TI2 | 5/20 | 0.44 |
| ▸ | SLC15A1 | P46059 | 2/20 | 0.42 |
| ▸ | FAP | Q12884 | 3/20 | 0.41 |
| ▸ | PREP | P48147 | 2/20 | 0.40 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.39 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.39 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.39 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.39 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.39 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6167493 | 0.90 | DPP4 (0.47) | DPP4DPP8DPP7DPP9SLC15A1 | |
| SCHEMBL7183513 | 0.90 | DPP4 (0.47) | DPP4DPP8DPP7DPP9SLC15A1 | |
| SCHEMBL6494483 | 0.90 | DPP4 (0.47) | DPP4DPP8DPP7DPP9SLC15A1 | |
| SCHEMBL6171477 | 0.85 | DPP4 (0.44) | DPP4DPP8DPP7DPP9FAP | |
| SCHEMBL6171475 | 0.85 | DPP4 (0.44) | DPP4DPP8DPP7DPP9FAP | |
| SCHEMBL7191378 | 0.83 | DPP4 (0.60) | DPP4DPP8DPP7DPP9FAP | |
| SCHEMBL7419137 | 0.83 | DPP4 (0.60) | DPP4DPP8DPP7DPP9FAP | |
| SCHEMBL7185307 | 0.83 | DPP4 (0.60) | DPP4DPP8DPP7DPP9FAP | |
| SCHEMBL7190168 | 0.79 | DPP4 (0.36) | DPP4DPP8DPP7DPP9FAP | |
| SCHEMBL8275517 | 0.79 | DPP4 (0.71) | DPP4DPP8DPP7DPP9FAP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6645995-B2 | Dipeptidyl peptidase-IV (DPP-IV); treating type II diabetes in a human; amino acid amides of 2-cyanopyrrolidine | NOVO NORDISK A/S (DK) | 2003-11-11 | — | — | US | disclosed |
| US-20020103384-A1 | Therapeutically active and selective heterocyclic compounds that are inhibitors of the enzyme DPP-IV | KANSTRUP ANDERS (DK) | 2002-08-01 | — | — | US | disclosed |
| US-6380398-B2 | COMPOUNDS SUCH AS (S,S)1-(2-AMINO-3,3-DIMETHYL-BUTYRYL)-2,5-DIHYDRO-1H-PYRROLE-2 -CARBONITRILE ADMINISTERED AS ANTIDIABETIC AGENTS; DIPEPTIDYL PEPTIDASE-IV (DPP-IV) | NOVO NORDISK A/S (DK) | 2002-04-30 | — | — | US | disclosed |
| US-20010031780-A1 | New therapeutically active and selective heterocyclic compounds that are inhibitors of the enzyme DPP-IV | NOVO NORDISK A/S (DK) | 2001-10-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010031780-A1 | New therapeutically active and selective heterocyclic compounds that are inhibitors of the enzyme DPP-IV | DPP4, DPP7, DPP9 | DPP4 1/4885DPP8 5/4885DPP7 2/4885 |
| US-20020103384-A1 | Therapeutically active and selective heterocyclic compounds that are inhibitors of the enzyme DPP-IV | DPP4, DPP7, DPP9 | DPP4 1/4885DPP8 5/4885DPP7 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.